Tevogen Inc. Grants Restricted Stock to CEO & CFO Tied to $1B Revenue Goal

What Happened
Tevogen Inc. filed an 8‑K (Sept 16, 2026) reporting that on Sept 14, 2026 the company granted restricted stock awards under its 2024 Omnibus Incentive Plan to CEO/Chair Ryan Saadi and CFO Kirti Desai. Dr. Saadi received 8,000,000 restricted shares and Mr. Desai received 750,000 restricted shares. Vesting is contingent on the Board’s certification that Tevogen achieves $1.0 billion in aggregate revenue by September 30, 2031. The restricted shares carry voting rights prior to vesting and are subject to forfeiture under certain conditions.

Key Details

• Grants: 8,000,000 Restricted Shares to Ryan Saadi; 750,000 Restricted Shares to Kirti Desai (grant date Sept 14, 2026).
• Performance condition: Vesting requires Board certification that the company reaches $1.0 billion in aggregate revenue by Sept 30, 2031.
• Ownership after grant: Dr. Saadi directly/indirectly owned 74.4% and Mr. Desai directly owned 6.3% of the 15,736,540 shares outstanding immediately after the grant.
• Forfeiture triggers: failure to meet the revenue goal by period end, termination of service before vesting, any pre-vesting transfer, an unassumed Change in Control, or certain detrimental conduct (which can also require cash repayment or share forfeiture for recently vested shares).

Why It Matters
These awards align executive pay with a concrete revenue milestone ($1.0B) and keep voting control with the executives before vesting. For investors, the grants signal management incentives focused on long‑term revenue growth, but also concentrate substantial equity with the CEO (over 74% ownership post‑grant). The restrictive vesting and forfeiture terms limit immediate dilution and transferability but tie potential future dilution and executive payoff to a challenging performance target.